We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Hormone Therapy Response Associated with Signaling Activity in Circulating Cancer Cells

By LabMedica International staff writers
Posted on 07 Nov 2012
Print article
A study monitoring hormone receptor activity in tumor cells from patients being treated for resistant metastatic prostate cancer has found that such monitoring may be useful for indicating which patients will be more likely to respond well to continued therapy.

Treatments that inhibit the androgen receptor (AR) pathway, androgen-deprivation therapy (ADT), are initially highly effective in most patients with metastatic prostate cancer (MPC); however, since cancer cells often develop resistance, secondary hormonal therapies are being tested to suppress androgen receptor reactivation. There are variable responses to such secondary therapy, but no reliable biomarkers are available to guide the use of AR pathway inhibitors in treating resistant MPC. A collaborative team of researchers led by Prof. Daniel A. Haber, MD, PhD, and director of the Massachusetts General Hospital Cancer Center (Charlestown, MA, USA) have now established a method using microfluidic capture of circulating tumor cells (CTCs) to isolate cancer cells from the blood of patients with MPC and single-cell immunofluorescence analysis to measure androgen receptor signaling activity in the individual CTCs.

Monitoring was performed on CTCs from patients with castration-resistant prostate cancer (CRPC), before and after therapeutic interventions. Prior to the initiation of ADT, the AR pathway was turned on in most CTCs from newly diagnosed patients. Initiation of first-line ADT induced a profound switch from “AR-on” to “AR-off” CTCs. In patients whose cancer had become resistant after initially responding well to androgen-deprivation therapy, the CTCs population became highly variable - some CTCs were AR-on, others AR-off, and still others had characteristics of both AR-on and AR-off. The presence of cells with a mixed AR signaling pattern was associated with an adverse treatment outcome. In addition, in patients treated with a new drug, abiraterone acetate, which achieves more complete androgen deprivation than earlier treatments, an increased percentage of AR-on CTCs despite abiraterone treatment was associated with decreased overall survival.

The assay may provide a valuable marker to help target such treatments to patients more likely to respond to second-line therapies. "This study is a proof of principle that it is possible to monitor, in patients with metastatic prostate cancer, the androgen receptor signaling pathway in real time, repeatedly and noninvasively," said Prof. Haber. He added, "As more drugs are developed that target the different pathways that drive the recurrence of metastatic prostate cancer in different patients, it will become essential to know which drug and which pathway is relevant in each patient. Our assay will be an effective way to interrogate the tumor and follow it during the course of treatment to monitor therapy response and the emergence of drug resistance."

The study was published early online October 23, 2012, in Cancer Discovery, a journal of the American Association for Cancer Research.

Related Links:
Massachusetts General Hospital Cancer Center
American Association for Cancer Research

New
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Automated Blood Typing System
IH-500 NEXT
New
Silver Member
Oncology Molecular Diagnostic Test
BCR-ABL Dx ELITe MGB Kit
New
Automatic Biochemistry Analyzer
Audmax 180 Evolution

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.